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ABSTRACT 25 
We used single cell Q-PCR on a micro-fluidic platform (Fluidigm) to analyse clonal, genetic 26 
architecture and phylogeny in acute myeloid leukaemia (AML) using selected mutations.  27 
Ten cases of NPM1c mutant AML were screened for 111 mutations that are recurrent in 28 
AML and cancer.  Clonal architectures were relatively simple with one to six sub-clones and 29 
were branching in some, but not all, patients.  NPM1 mutations were secondary or sub-clonal 30 
to other driver mutations (DNM3TA, TET2, WT1 and IDH2) in all cases.  In three of the ten 31 
cases, single cell analysis of enriched CD34
+
/CD33

 cells revealed a putative pre-leukaemic 32 
sub-clone, undetectable in the bulk CD33
+
 population that had one or more driver mutations 33 
but lacked NPM1c.  Cells from all cases were transplanted into NSG mice and in most (8/10), 34 
more than one sub-clone (#2-5 sub-clones) transplanted.  However, the dominant 35 
regenerating sub-clone in 9/10 cases was NPM1
+
 and this sub-clone was either dominant or 36 
minor in the diagnostic sample from which it was derived.  This study provides further 37 
evidence, at the single cell level, for genetic variegation in sub-clones and stem cells in acute 38 
leukaemia and demonstrates both a preferential order of mutation accrual and parallel 39 
evolution of sub-clones. 40 
 41 
INTRODUCTION 42 
Although almost all cancers originate in a single cell, the sequential acquisition of necessary 43 
additional mutations fuels sub-clonal diversity which is then a substrate for positive or 44 
negative selection within the tissue ecosystems and with therapy 
1, 2
.  This process frequently 45 
results in complex cell population structures and highly variegated genetics 
3-5
. 46 
The genomics of AML have been described in considerable detail, revealing multiple 47 
sub-types 
6, 7
 and sequential transition between clinically silent pre-leukaemia and overt 48 
disease 
8, 9
.  Sub-clonal architectures in diagnostic samples have been inferred from allele 49 
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burdens 
10
 and appear to be relatively simple compared to that observed in many common 50 
cancers 
11, 12
. 51 
The extent of sub-clonal diversity and phylogenetic architecture is, however, best 52 
derived from single cell analysis.  This is challenging however in terms of accuracy and 53 
depth, but has proven illuminating in some solid tumours 
13
 and ALL 
3
. 54 
Only a few studies to date have reported single cell genetics and inferred sub-clonal 55 
phylogenies in AML.  Paguirigan et al 
14
 used single cell, multiplexed Q-PCR to investigate 56 
patterns of segregation of two concurrent mutations in AML – FLT3-ITD and NPM1c 57 
mutations.  The data revealed significantly more sub-clonal diversity than could be inferred 58 
from analysis of the bulk population.  Klco et al 
15
 fractionated immuno-phenotypically 59 
distinct cell populations from a patient with AML and sequenced the amplified DNA from 60 
single cells for ten known mutations.  From these data, they could infer a branching sub-61 
clonal architecture.  Jan et al used a Q-PCR assay on colonies derived from sorted single cells 62 
derived from two cases of AML and were able to infer an ordered sequence of mutations 
8
.  63 
Quek et al screened single cells for targeted mutations in immunophenotypically-defined 64 
subsets and identified putative clonal sequences and mutation order in six cases 
16
. 65 
In our previous studies in ALL, we used multi-colour FISH or multi-plexed Q-PCR in 66 
a micro-fluidic platform (Fluidigm) to detect sub-clonal variegation and clonal architecture 
3, 67 
17
.  In this study, we sought to replicate our observations on ALL for AML, selecting the 68 
subset of cases with NPM1c mutations.  NPM1c
+
 cases constitute around 27% of adult AML 69 
with a variable but overall intermediate risk 
7
.  The questions posed included the extent of 70 
sub-clonal complexity that was discernible, sequential order of mutations and whether stem 71 
cells or leukaemia propagating cells, assayed by xeno-transplantation, were genetically 72 
variable. 73 
 74 
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MATERIALS AND METHODS 75 
Sample cohort 76 
A total of ten well-characterized NPM1 mutant AML samples 
18
 were selected for further 77 
study according to engraftment potential.  Blood and marrow samples were collected from 78 
patients with AML after written informed consent at St Bartholomew’s Hospital.  The 79 
protocol was approved by the East London and City Research Ethics Committee.  All studies 80 
comply with the rules of the revised Helsinki protocol.  These had all been found to 81 
successfully transplant in NOD/SCID mice 
18
.  This selection criterion may have biased our 82 
analysis towards poorer prognosis cases 
7, 18
.  Available peripheral blood was collected prior 83 
to treatment at presentation (n = 10) and from matched relapse (n = 3).  Mononuclear cells 84 
were obtained by density gradient centrifugation.  Details of the patient samples are listed 85 
(Table 1). 86 
FACS cell sorting according to immunophenotype details can be found in 87 
Supplementary Information. 88 
 89 
Mutation analysis 90 
A targeted screening approach investigating 111 genes (Table 2) was used to identify 91 
mutations and DNA coding region alterations in each NPM1c AML as previously described 
7
 92 
that could potentially be tracked in single cells.  The analysis is based on variants that can be 93 
classified as recurrent driver mutations, using widely accepted genetic criteria.  These 94 
included non-synonymous base substitutions and small (<200-bp) insertions or deletions 95 
(indels).  Table 3 lists the probes used for mutant versus wild type sequences and PCR 96 
primers. 97 
 98 
Sequencing data 99 
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For the targeted mutation screening of each leukaemia, two populations of interest were 100 
stained and sorted as described in Supplementary Information and DNA extracted (Qiagen 101 
DNA blood kit according to manufacturers’ instructions): peripheral blood T-cells 102 
(CD3
+
/CD33
-
) (as a control) and mononuclear blast cells (CD3
-
/CD33
+
).  The latter had <1% 103 
CD34
+
 cells and we refer to this population as CD34
-
. 104 
 For details of library preparation, sequencing, alignment and analysis, please refer to 105 
Supplementary Information. 106 
 107 
Xeno-transplantation 108 
NOD/SCID (Il2rg
-/-
) mice (Jackson Laboratory, Bar Harbor, ME) were injected intravenously 109 
(3 mice per AML sample) with 9-10 million AML cells after T-cell depletion by Easysep T-110 
cell enrichment cocktail (Stem Cell Technologies).  Mice were bled by tail veins at 12-14 111 
weeks and blood leukocytes investigated by FACS (as described in Supplementary 112 
Information and Supplementary Figures 2 and 3) using anti-human and anti-mouse CD45 113 
antibodies to determine the percentage of leukaemic cell engraftment.  For details of how 114 
successful/undetectable/minimal grafts were managed and serial transplantations were carried 115 
out, please refer to Supplementary Information. 116 
 117 
Single cell sorting and multiplex Q-PCR analysis 118 
Single cell sorting was carried out (see Supplementary Information and Supplementary 119 
Figure 1) according to our established published Q-PCR single cell (Fluidigm) protocol 
17
.  120 
Briefly, from each case single AML cells (either CD33
+
/CD34
-
/CD3
-
 (blast population), 121 
CD3
+
/CD33
-
 (internal control), CD34
+
/CD33
- 
(putative stem cell), CD45
+
 (human cells post-122 
transplant) or cord blood cells (normal diploid control) were sorted into individual wells of a 123 
96 well plate, lysed and DNA target amplification completed for regions of interest 124 
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encompassing patient specific mutations or DNA alterations.  Allelic discrimination Q-PCR 125 
assays were designed specifically for each mutation in every patient.  Standard Q-PCR assays 126 
targeting unique FLT3-ITDs were designed for each positive patient.  Genes targeted in each 127 
case are listed in Table 1.  The ß2M locus, located in a diploid region of the genome, was 128 
used as a control.  Q-PCR completed using the 48 x 48 dynamic array and the BioMark HD 129 
from Fluidigm. 130 
Several approaches were adopted during this experiment to optimise and confirm the 131 
presence of a single cell and ensure all assays performed efficiently under experimental 132 
conditions 
17
; a brief description can be found in Supplementary Information and 133 
Supplementary Figure 4. 134 
 135 
Maximum parsimony 136 
Maximum parsimony searches for sub-clonal phylogenies were conducted using heuristic 137 
searches as previously described 
17
; a brief description can be found in Supplementary 138 
Information. 139 
 140 
RESULTS 141 
Our targeted exomic screening approach identified a number of common or recurrent driver 142 
SNV mutations in each patient’s diagnostic sample (Table 1); similar to those previously 143 
described for NPM1c AML 
7, 19-21
.  Five of the ten cases had both DNM3TA and TET2 144 
mutations, reflecting the selection of driver mutations that cooperate to confer fitness 145 
advantage of haemopoietic stem cells 
22
. Allele frequencies varied greatly suggested that 146 
many mutations were probably sub-clonally distributed. 147 
 Individual cells sorted as CD34
+
/CD33
-
 or CD33
+
/CD3
-
 were assayed by multiplex Q-148 
PCR for each driver mutation identified in that patient’s sample.  We similarly assessed 149 
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individual cells (unsorted) from NSG mice in which T-cell depleted AML cells from each 150 
patient had been transplanted.  From those single cell data, we are able to infer a probable 151 
clonal phylogeny for each case with genetically distinct sub-clones, the immunophenotype 152 
and the clonal derivation of leukaemia that regenerated in NSG mice.  We take the latter as a 153 
read-out of sub-clones with self-renewal or stem cell activity. 154 
 155 
Clonal architectures 156 
Figure 1 summarises the data from all ten cases (see Supplementary Information for more 157 
detailed data).  This includes an identifier (t = transplant) of sub-clones that successfully 158 
transplanted into mice (t1, t2 and t3 refer to individually transplanted mice using diagnostic 159 
material from each patient).  The phylogenetic or sub-clonal architectures inferred are 160 
relatively simple and either linear or branching (three patients).  The analyses are relatively 161 
insensitive however with minor clones below 5% being difficult to detect.  It is very likely 162 
that we are significantly under-estimating clonal complexity and will have missed minor sub-163 
clones that could be clinically relevant, emerging at relapse 
23
. 164 
 In two patients (#1 and #3; Fig 1), there were more than one equally parsimonious 165 
phylogenetic trees (illustrated by alternative dotted lines connecting sub-clones).  We depict 166 
all equally parsimonious trees for patients #1 and #3 in Supplementary Figures 5 and 6. 167 
 The number of identifiable sub-clones varied from one to six.  In four patients (#4, #5, 168 
#7 and #8) the small, putative stem cell CD34
+
/CD33
-
 fractions contained a genetic sub-clone 169 
that was not discernible in the large CD33
+
 blast population.  These cells had fewer 170 
mutations, lacked NPM1c mutation and could represent pre-leukaemic cells 
8, 9
.  171 
 We did not detect DNM3TA or other putative founder mutations in the T cells by 172 
single cell analysis.  However, in most cases reported by Shlush et al 
24
, the mutant DNM3TA 173 
allele frequency in T cells was low and so could have been missed in our samples in which 174 
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only a maximum of 48 single T cells were assayed.  In the total or bulk population of NPM1c 175 
AML-derived T cells that were subject to targeted sequencing in our series of patients, the 176 
calculated allele frequency for DNM3TA mutations and other putative driver mutations in 177 
AML cells ranged from 0.64% to 4.35% in the T cell population. 178 
NPM1c mutations were always preceded by mutations previously considered as 179 
possible founders; DNMT3A, IDH2, WT1, TET2 as well as some additional mutations that are 180 
less well validated as early events in NPM1c AML including NRAS, ZRSR2 and CBL.  FLT3 181 
mutations and FLT3-ITDs were found to occur both before and after the acquisition of 182 
NPM1c but were always sub-clonal to putative founder mutations. 183 
 184 
Match relapsed cases 185 
In the three NPM1c AMLs with matched relapse samples (#8, 9, 10), we found high levels of 186 
NPM1c sub-clones in the CD34
+
/CD33

 population at diagnosis ranging from 43% -100%.  187 
In the single case in which the CD34
+
/CD33

 population could be assessed at relapse (patient 188 
#8), the size of the NPM1c sub-clone had increased from 43% to 95%.  In these AMLs it was 189 
also possible to identify sub-clones at relapse or in the mice after transplant of the diagnostic 190 
or relapsed material that had acquired more mutations in addition to those found in the major 191 
clone at diagnosis (in #9, #10; see Table 1).  Some of these mutations could not be tracked by 192 
Q-PCR but were identified by direct sequencing (Table 1).  Patient #10 had two FLT3 sub-193 
clonal mutations (detected by sequencing), one at diagnosis (10.03%) rising to 41.64% whilst 194 
the other was only detected at relapse (41.16%).  Neither of these FLT3 mutations could be 195 
tracked, so they do not appear in patient #10 clonal structure (Fig 1). 196 
 197 
Reiterative mutations 198 
Reiterated mutations in individual driver genes were identified in some cases.  In patient #3, 199 
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the two distinctive FLT3 mutations were segregated in distinctive sub-clones.  Similarly, in 200 
patient #1, the two distinctive TET2 mutations were present in separate (minor/major) sub-201 
clones.  In contrast, in patient #7 the two TET2 mutations were in the same sub-clone and 202 
probably bi-allelic.  Phylogenetic architectures suggested that NPM1c mutations may also 203 
have been reiterative in some cases, for example with patient #3 (and possibly patient #1) but 204 
the invariant nature of this mutation makes this more ambiguous. 205 
 206 
Stem cell read-outs in transplants 207 
The single cell genetics of regenerated leukaemias in mice (see t1,t2,t3 % in Fig 1) allowed 208 
us to infer the sub-clonal origins of leukaemias and hence the genetic composition and its 209 
variation in the stem or leukaemia propagating cell compartment of these AML.  The clonal 210 
read-outs in the transplants were diverse but some patterns emerged. 211 
 In eight cases (patients #1, #2, #3, #4, #5, #6, #8 at diagnosis, #10 at relapse) two to 212 
five sub-clones present in the diagnostic sample regenerated in the mice.  However in each 213 
case, one sub-clone was dominant, proportionally and this sub-clone always contained 214 
NPM1c. 215 
 In one patient (#7), only one sub-clone was present at low levels (0.39% CD34
+
 cells) 216 
in a single mouse and, surprisingly, this corresponded to the most ancestral sub-clone in the 217 
diagnostic sample which had DNMT3A as its sole identifier mutation.  These are most likely 218 
pre-leukaemic cells.  In patient #8, two sub-clones read-out in mice from the diagnostic 219 
sample.  The dominant or largest sub-clone in all three mice harboured not only a NPM1c but 220 
also a TET2 mutation; this clone was below the detection limit in the diagnostic sample itself 221 
(indicated by dotted circle in Fig 1).  The relapse sample from patient #8 contained only one 222 
NPM1c sub-clone corresponding to the major sub-clone seen at diagnosis.  However, in the 223 
transplant of this sample, a NPM1c-negative sub-clone, ancestral to the relapse sub-clone, 224 
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represented 100% of the regenerated leukaemia. 225 
 Finally, in patient #9, there was only one clone discernible both at diagnosis and 226 
relapse and this clone read-out consistently in transplants of diagnostic and relapse samples. 227 
 228 
DISCUSSION 229 
These single cell data provide definitive identification of clonal architectures and preferential 230 
order of mutations, furthering endorse the concept of sub-clonal complexity in myeloid 231 
leukaemia 
7, 14-16
.  However, the current limits of single cell screening means that we will 232 
have under-estimated the extent of sub-clonal genetic diversity that can be revealed by ultra-233 
deep sequencing 
25
 and by new technologies that allow interrogation of thousands of cells 
26
.  234 
This has implications for clonal architecture and phylogeny.  For example, in diagnostic 235 
samples from several patients (#2, #3, #4, #8, #9), the sub-clone with the most simple genetic 236 
composition at the base of the phylogenetic tree harboured more than one mutation.  The 237 
phylogenetic structure is therefore likely to have missed earlier, sequential (pre-leukaemic) 238 
clones 
8
. 239 
Different driver mutations have epistatic or synergistic functional impacts in AML 
7, 
240 
22, 27
 and the order of mutation accrual may impact on stem/progenitor cell function and 241 
clinical features 
28
.  Our data provides direct evidence that NPM1c mutation is a sub-clonal 242 
and therefore secondary mutation rather than a truncal or initiating lesion, as previously 243 
suggested 
29
.  This concurs with the observations of Shlush et al 
9
 who found (in ten patients 244 
with AML) that DNMT3A mutations in AML were present in differentiation competent 245 
haemopoietic stem cells and putative pre-leukaemic clones.  NPM1 mutations, in contrast, 246 
were absent from such cells but present in blasts cells with a myeloid progenitor cell 247 
phenotype presumed to be descended from the DNMT3A mutant clones.  Similarly, Corces-248 
Zimmerman et al 
30
 found that NPM1c mutations were absent in purified haemopoietic stem 249 
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cells, in contrast to putative founder mutations including DNMT3A, IDH1, IDH2 and ASXL1.  250 
In cases of AML analysed at the single cell level, Jan et al 
8
 (one case) and Quek et al 
16
 251 
(three cases) documented that NPM1c was sub-clonal or secondary to TET2 mutations.  252 
However, Quek et al 
16
 also identified, in two cases, very rare CD34
+
 cells that had NPM1 253 
mutations but not other mutations found in the bulk leukaemic cells raising the possibility 254 
that NPM1 might occasionally be a founder mutation in pre-leukaemic cells.  The 255 
preservation of diagnostic DNMT3A but not NPM1c mutations in remission 
9, 31
 and in a 256 
small minority of relapses is also commensurate with the predominantly secondary, sub-257 
clonal nature of NPM1c 
32, 33
.  As is the presence of DNMT3A and TET2 but not NPM1c 258 
mutations in covert pre-malignant clones of normal, ageing adults 
34
. 259 
A preferential order of mutation may reflect genetic network or cell context 260 
dependencies.  NPM1c (and FLT3 mutations) might be potent drivers only when arising in 261 
myeloid progenitor cells with enhanced self-renewal provided by mutations in epigenetic 262 
mutations such as DNM3TA or TET2. 263 
In the bulk blast cell population, DNMT3A and NPM1c mutations were present at 264 
similar high allele burden suggesting these were concurrent in the same cells 
9
.  In another 265 
study however, NPM1c allele burden was consistently less than that of other drivers including 266 
DNMT3A commensurate with a sub-clonal origin 
19
.  In our series, the allele burden for 267 
NPM1c was consistently less than that of other putative founder mutations including 268 
DNMT3A, TET2 and IDH2 (Fig 1).  The existence of clones ancestral to those with NPM1c 269 
mutations was clearly evident (in 8/10 cases) in the minor population sub-fractionated as 270 
CD34
+
/CD33
-
.  This again accords with the data of Shlush et al 
9
. 271 
 Mouse models with transgene or knock-in NPM1c have been developed to assess the 272 
role of NPM1 in leukaemogenesis 
35
.  By itself NPM1 expressed in haemopoietic stem cells 273 
produces a myeloproliferative disorder and a low penetrance of late occurring AML.  A high 274 
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frequency of AML does develop in NPM1c mice subjected to insertional mutagenesis 
36
 or in 275 
compound mutant mice with both NPM1c and FLT3-ITD 
37, 38
.  These modelling data testify 276 
to the functional impact of NPM1c on myeloid cells and leukaemogenesis but underscore that 277 
it is, at best, a weak initiating or founder lesion for AML. 278 
 The order of mutations and their position in the phylogenic tree is relevant to the 279 
selection of mutated gene for targeted therapy 
4
.  In the cases of NPM1c
+
 AML, the 280 
phylogenetic studies highlight DNMT3A and TET2 as truncal mutations as reported 281 
previously 
8, 9
.  Effective therapeutic targeting of either NPM1c or FLT3 mutations might be 282 
expected to debulk the leukaemia but with only transient benefit.  However, persistence or 283 
increase of MRD in AML via detection of NPM1c transcripts is strongly predictive of relapse 284 
39
 and in the great majority (>95%) of cases of NPM1c
+
 AML that relapse, the relapsing 285 
clone is NPM1c
+
 
40
.  In contrast, persistence of founder mutations (DNMT3A, TET2, ASXL1) 286 
or pre-leukaemic clones, is not predictive of relapse 
41
  This reflects the strong driver status of 287 
NPM1c mutations and the malignant potential of NPM1c sub-clones which is likely 288 
contingent upon the genetic background of founder (truncal) mutations (i.e. by epistasis) and 289 
additional co-existing sub-clonal mutations (e.g. in FLT3).  Effective targeting of NPM1c 290 
could, therefore, be very beneficial in restraining progression of disease. 291 
 There was evidence for reiterated driver mutations in sub-clones of several cases in 292 
this study.  This has been described before in ALL 
3
 and other cancers 
42
.  Mutations that are 293 
highly recurrent between patients with a sub-type of leukaemia (or any cancer) might be 294 
expected to occur more than once within a leukaemia from single patients.  Functionally, this 295 
could reflect either the fitness advantage of bi-allelic mutations of the same gene in the same 296 
cells or convergent evolution of sub-clones contingent upon prevalent selective pressures or 297 
preferential, epistatic partnership with earlier, common mutations 
43
. 298 
A comparison of clonal structures in three cases of matched diagnosis and relapse 299 
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samples (#8, #9, #10) allowed us to infer the possible sub-clonal origins of the relapses.  In 300 
one patient (#9), there was only one clone detectable at diagnosis and that same clone was the 301 
only clone observed at relapse.  In case #8, the single relapse detected corresponded to one of 302 
two clones present at diagnosis.  However, sequencing also revealed a TET2 mutation at low 303 
allele burden (1.03%) at relapse.  The allele burden for this mutation at diagnosis was 304 
undetectable.  However, when the diagnostic sample was transplanted into mice, a sub-clone 305 
with that ‘relapse’ TET2 mutation was the dominant clone (refer to Figure 1 for case #8). 306 
 In patient #10, there were three sub-clones at diagnosis and all three were present in 307 
the relapse sample.  These data raise the possibility that relapse in AML is not necessarily 308 
more clonal and this should be further explored as it has important implications for the basis 309 
of drug resistance. 310 
 Xeno-transplant read-outs depend upon the genetic background of the immuno-311 
deficient mice 
15
 and may not faithfully reflect the true diversity of propagating cells in AML.  312 
Furthermore, we made no attempt to titrate leukaemia propagating activity by varying the 313 
number of cells transplanted or by serial transplantation (except in patient #1).  We note 314 
however that replicate mice provide very similar read-outs which suggest intrinsic, functional 315 
properties of AML sub-clones are being registered.  The only conclusion we wish to draw 316 
from these limited transplant experiments is that multiple sub-clones from individual patients 317 
transplant indicating, as we showed previously for ALL 
3
 and glioblastoma 
44
, that individual 318 
leukaemia’s contain several, genetically distinct cells with self-renewing or leukaemia 319 
propagating activity.  These cells will provide a diverse pool of cells distributed throughout 320 
the phylogenetic tree and from which relapse or drug resistance can emerge as recently 321 
demonstrated by Shlush et al 
24
.  As such they function as cellular units of evolutionary 322 
selection 
45, 46
.  However, sub-clones have variable repopulating capacity 
47
 and as previously 323 
reported in AML 
15
, one NPM1c sub-clone dominated leukaemia regeneration in mice.  This 324 
14 
 
may reflect the increased malignant potential of this sub-clone and the contribution of 325 
NPM1c
+
 cells to relapse in >95% of cases 
40
.  In all our six cases where the diagnostic clone 326 
had both NPM1c and FLT3 ITD or FLT3 mutations, the dominant sub-clone in transplant 327 
readouts had both mutations.  Competitiveness of sub-clones with this genotype in a 328 
xenotransplant context might be relevant to the very poor prognosis of AML cases that 329 
harbour a combination of mutants in DNMT3A, NPM1c and FLT3 
7
. 330 
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FIGURE LEGENDS 479 
Figure 1.  Clonal phylogenies, inferred by maximum parsimony, and sub-clone genotypes in 480 
10 patients. 481 
Genetically distinct sub-clone percentages (as a fraction of the total population) are indicated 482 
next to each clone; e.g. patient 1, most primitive sub-clone, CD34
+
/CD33
-
 first and  483 
CD33
+
/CD34
-
/CD3
- 
second percentages indicated as 18%/5% respectively.  This indicates 484 
that this sub-clone was found in 18% of the total CD34
+
/CD33
-
 cells investigated and 5% of 485 
the total CD33
+
/CD34
-
/CD3
- 
cells investigated (for the relapse samples of patients 9 and 10 486 
only bulk cells without phenotype consideration could be sorted, as the samples available 487 
were from fixed cytogenetic preparations; the sub-clone is shown as a single percentage).  488 
Those sub-clones that grew in mice are indicated with horizontal black arrows.  t1-3 (%).  T, 489 
transplant.  1-3 individual mice.  % fraction of human cells in mouse bone marrow.  Sub-490 
clone denoted by dotted circle is below detection limit in diagnostic sample but present in 491 
mouse transplant read-out.  Dotted arrows lines between sub-clones (case #1 and #3) 492 
indicates alternative clonal phylogenies.  In case #3, there are 4 possible equally 493 
parsimonious phylogenetic trees (details in Supplementary Information Figures 5 and 6).  494 
Further details on each of the individual 10 patients’ clonal analyses are given in 495 
Supplementary Information. 496 
 497 
